ATE292677T1 - Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe - Google Patents

Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe

Info

Publication number
ATE292677T1
ATE292677T1 AT00964563T AT00964563T ATE292677T1 AT E292677 T1 ATE292677 T1 AT E292677T1 AT 00964563 T AT00964563 T AT 00964563T AT 00964563 T AT00964563 T AT 00964563T AT E292677 T1 ATE292677 T1 AT E292677T1
Authority
AT
Austria
Prior art keywords
methods
compositions
dna
agents
damageing
Prior art date
Application number
AT00964563T
Other languages
English (en)
Inventor
Masashi Suganuma
Takumi Kawabe
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP26939899A external-priority patent/JP2001086991A/ja
Priority claimed from JP34032299A external-priority patent/JP2001157585A/ja
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Application granted granted Critical
Publication of ATE292677T1 publication Critical patent/ATE292677T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT00964563T 1999-09-22 2000-09-21 Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe ATE292677T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26939899A JP2001086991A (ja) 1999-09-22 1999-09-22 オリゴペプチド
JP34032299A JP2001157585A (ja) 1999-11-30 1999-11-30 抗癌療法の増強剤とそのスクリーニング方法
PCT/IB2000/001438 WO2001021771A2 (en) 1999-09-22 2000-09-21 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents

Publications (1)

Publication Number Publication Date
ATE292677T1 true ATE292677T1 (de) 2005-04-15

Family

ID=26548750

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964563T ATE292677T1 (de) 1999-09-22 2000-09-21 Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe

Country Status (11)

Country Link
US (2) US6881575B1 (de)
EP (1) EP1218494B1 (de)
JP (1) JP4610828B2 (de)
AT (1) ATE292677T1 (de)
AU (1) AU7548500A (de)
CA (1) CA2385257A1 (de)
DE (1) DE60019318T2 (de)
DK (1) DK1218494T3 (de)
ES (1) ES2239037T3 (de)
PT (1) PT1218494E (de)
WO (1) WO2001021771A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295540C (zh) * 2001-12-17 2007-01-17 奥林巴斯株式会社 显微镜系统
KR100863090B1 (ko) * 2002-01-17 2008-10-13 다케다 파머수티컬 컴패니 리미티드 항증식 활성을 지니고／지니거나 핵산 손상제 또는 처리제를 증강시키는 펩티드 및 펩티드모방체
EP1575881B1 (de) 2002-01-18 2009-05-27 Novozymes A/S Alanin-2,3-aminomutase
US7030111B2 (en) * 2002-06-06 2006-04-18 Canbas Co., Ltd. Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments
PL378372A1 (pl) 2003-01-09 2006-04-03 Pfizer Inc. Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
DE602004006852D1 (de) 2003-04-17 2007-07-19 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5ü-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
US20070172425A1 (en) * 2003-05-29 2007-07-26 Dongfang Liu Testing cell cycle regulation effect of a compound using a hollow fibre cell implant
CN1812805A (zh) * 2003-06-25 2006-08-02 坎巴斯有限公司 具有免疫调节活性、抗炎活性和抗病毒活性的肽和肽模仿物
US7358046B2 (en) * 2003-08-08 2008-04-15 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
CA2536321A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
AU2004274013A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation
DE602005027739D1 (de) 2004-06-30 2011-06-09 Janssen Pharmaceutica Nv Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs
MX2009011025A (es) 2007-04-11 2010-01-25 Canbas Co Ltd Compuestos con actividad anticancer.
NZ580982A (en) 2007-05-08 2012-05-25 Schering Corp Methods of treatment using intravenous formulations comprising temozolomide
PE20091924A1 (es) * 2008-05-14 2010-01-04 Takeda Pharmaceutical Compuesto peptidico y su uso
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
AU2017223226A1 (en) * 2016-02-23 2018-08-30 Takeda Pharmaceutical Company Limited Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain
CN110904070A (zh) * 2019-12-05 2020-03-24 王连生 一种促进心肌再生的重组人chk1蛋白激酶水凝胶及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
WO1998030680A2 (en) * 1997-01-13 1998-07-16 Pharmacia & Upjohn Company Special catalytic domains of cdc25c phosphatase

Also Published As

Publication number Publication date
DK1218494T3 (da) 2005-08-08
US20050059116A1 (en) 2005-03-17
WO2001021771A2 (en) 2001-03-29
US7851592B2 (en) 2010-12-14
JP4610828B2 (ja) 2011-01-12
US6881575B1 (en) 2005-04-19
PT1218494E (pt) 2005-08-31
ES2239037T3 (es) 2005-09-16
AU7548500A (en) 2001-04-24
EP1218494A2 (de) 2002-07-03
CA2385257A1 (en) 2001-03-29
EP1218494B1 (de) 2005-04-06
JP2003518368A (ja) 2003-06-10
DE60019318D1 (de) 2005-05-12
DE60019318T2 (de) 2006-03-09
WO2001021771A3 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
DE60019318D1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
HRP20070189A2 (en) Use of erythropoietin
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
ATE511503T1 (de) Aryl- und heteroarylharnstoff-chk1-inhibitoren zur verwendung als radiosensibilisatoren und chemosensibilisatoren
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
BRPI0409367A (pt) derivados de piperidina inibidores de renina
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
BRPI0616630B8 (pt) compostos de pirazol substituídos
TW200801008A (en) Protein kinase inhibitors
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE473728T1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1218494

Country of ref document: EP